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Abstract
The high-aspect-ratio nanoparticles were proved to be internalized much more rapidly and efficiently by cancer
cells than the nanoparticles with an equal aspect ratio. Herein, a kind of high-aspect ratio, pointed-end
nanoneedles (NDs) with a high drug loading (15.04 %) and the prolonged drug release profile were fabricated
with an anti-tumor drug—10-hydroxycamptothecin (HCPT)—via an ultrasound-assisted emulsion crystallization
technique. It is surprising to see that the cellular internalization of NDs with an average length of 5 μm and an
aspect ratio of about 12:1 was even much faster and higher than that of nanorods with the same size and the
nanospheres with a much smaller size of 150 nm. The results further validated that cellular internalization of
the nanoparticles exhibited a strong shape-dependent effect, and cellular uptake may favor the particles with
sharp ends as well as a high-aspect ratio instead of particle size. The NDs with enhanced cytotoxicity would
lead to a promising sustained local drug delivery system for highly efficient anticancer therapy. More importantly, the
fabrication of NDs opens a door to design new formulations of nanoneedle drug delivery systems for highly
efficient cancer.
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Background
Cancer, causing about eight million deaths/year [1], has
become the most common factor in worldwide mortal-
ity. Chemotherapy is one of the most commonly used
strategies in cancer therapy, but their efficacy is largely
limited by suboptimal pharmacokinetic properties, such
as low stability, poor absorption, toxicity, distribution,
and elimination [2]. Therefore, over the decade, the con-
centration of research was focused on improving the ef-
ficacy of the chemotherapy. In this regard, some novel
drug delivery systems, such as microspheres, nanoparti-
cles, and liposomes, have been proposed. It follows that
mutifunctional particles with long-circulating [3, 4], tar-
geting [5–7], imaging [8, 9], and pH-sensitivity [10, 11]
have been developed, which further improve their phar-
macokinetic properties.
The cellular uptake of the particles is an important
factor to the therapeutic effect of the drug delivery sys-
tems. To facilitate the cellular uptake, the concentration
has been focused on controlling the size of the particles.
It is formerly accepted that the size of nanoparticles may
play a paramount role in cellular uptake [12–17], although
its effect on the uptake into non-phagocytic cells is still
not fully understood. It is believed that the upper limit of
the size of the particles that could be internalized into
non-phagocytic cells via non-specific endocytosis was
150 nm [18–21]. Rejman et al. found that spherical nano-
particles, with a size of up to 500 nm, could be taken up
by non-phagocytic cells, whereas spherical particles with a
diameter of 1 μm could not [22]. As the size increases, the
amount and the speed of the internalization of the beads
were found to be significantly reduced compared with the
50-nm beads [22]. He et al. came to the similar conclusion
that smaller particles were more likely to be uptake by
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non-phagocytic cells [23]. As to the particles smaller than
100 nm, there would be an optimum size of 50 nm for cel-
lular uptake [23]. According to the aforementioned studies
and others’ work [12, 24–27], the non-phagocytic cellular
uptake shows a clear trend: the uptake.
We notice that all these studies are performed using
spherical nanoparticles and neglect the influence of par-
ticle shape. This is most likely due to the lack of easy-to-
use methods available to control the particle shape.
Since the last decade, the non-spherical particle shape is
attracting more and more attention for their potential
effect on drug delivery, due to the progress made in
attaining diversely shaped particles [28–33]. Although
the effect of shape on drug delivery has not been thor-
oughly examined, there has already been evidence show-
ing that many properties of the particles, the degradation,
the biodistribution, and the cellular internalization of the
particles, will be particle shape dependent [34–40]. Non-
spherical particles have already been identified to possess
particular pharmacokinetic properties which may be more
favorable towards the therapeutic intent [41]. Non-
spherical particles with asymmetric shapes could offer
unique degradation profiles, since the particle shapes are
changing over time [38]. Zero-order release, the goal of
many sustained drug delivery systems, was achieved with
a hemi-spherical particle which only allowed degradation
on the surface. Non-spherical particles have also been
found to exhibit distinct in vivo distribution profiles,
which may provide a new means for targeting of specific
organs or tissues, such as the spleen [42], the lungs [43],
and tumor tissues [44, 45]. And above all, shape plays an
important role in the cellular internalization, hence largely
affecting the treatment result. Because when the particles
reach the target tumor site, by systemic administration or
direct local administration, they must be able to enter can-
cer cells to reach the therapeutic targets within the cells
and kill them. In recent studies, it was found that the can-
cer cells preferred particles with a high-aspect ratio. Nano-
rods were found to penetrate tumor cells more rapidly
than nanospheres, perhaps due to improved transport
through pores [46]. The cellular uptake by A375 human
melanoma cells increases in number and speed with the
aspect ratio of mesoporous silica nanoparticles of constant
diameter [47]. In another systematic study, the effect of
the particle shape of cationic, cross-linked, and PEG-based
hydrogel particles on cellular uptake was examined with
HeLa cells [48]. It is found that the cubic particles with a
size of 3 um could be internalized by HeLa cells, although
it was only limited. Interestingly, the internalization of the
rod-shaped, high-aspect-ratio nanoparticles occurred to
be with much higher efficacy than that of nanoparticles
with an equal aspect ratio.
Although, the result, that the high-aspect ratio could
increase the cellular uptake, has been proven by more
and more studies, few reports indicated that it has been
used in the drug delivery system. According to the afore-
mentioned research results, we could infer that antican-
cer drug-loaded nanoparticles with a high-aspect ratio
perhaps show an enhanced effect in cancer cell intake,
which could optimize the efficiency of drug delivery, and
eventually benefit the cancer therapy. However, not many
reports were found about the property of the pointed-end
non-spherical particles. Hence, in this study, we will
fabricate the high-aspect ratio, pointed-end, and 10-
hydroxycamptothecin (HCPT)-loaded nanoneedles (NDs)
with high drug loading and sustained drug release. To im-
plement this idea, the anti-solvent co-precipitation of the
HCPT and PEG-b-PLGA (monomethoxy polyethylene
glycol-block-poly (lactide-co-glycolide)) will be employed
under sonication to control the nucleation of NDs with
nanocrystalline HCPT. In the fabrication, the core of
HCPT will be wrapped with PEG-b-PLGA as steric stabi-
lizers. In vitro studies will then be systematically carried




All chemicals were analytical grade and used as received
without further purification. The ultrapure water (18 M
Ω∙cm-1) was used throughout the work. The 10-HCPT
(purity >99 %) was purchased from Lishizhen Pharma-
ceutical Co., Ltd. The monomethoxy (polyethylene
glycol)-poly (lactide-co-glycolide) (MPEG-PLA, PEG:
10 %, 5000 Da, PLA: 28000 Da, 85/15) was obtained
from Daigang Biotechnology Co., Ltd.
Preparation of the HCPT-Loaded NDs
The HCPT-loaded NDs were prepared via an ultrasound-
assisted emulsion crystallization technique followed by the
lyophilization treatment. Briefly, 5 mg HCPT and 5 mg
PEG-b-PLGA were first co-dissolved in 5 mL acetone
as the oil phase, which was then added dropwise into
deionized water of 40 mL in volume in 5 min with son-
ication at the power of 200 W in an ice bath. After-
wards, the remaining organic solvent was removed by the
rotary vacuum evaporation at 37 °C, and the resultant
aqueous solution was filtered through a 1-μm cellulose
acetate filter membrane to remove small drug nanocrystals
as well as copolymer aggregates. The produced suspension
was lyophilized for 24 h to get the dried powder.
Preparation of the HCPT-Loaded NSs
The HCPT-loaded nanospheres (NSs) were prepared by
a facile dialysis method. In brief, 100 mg of PEG-b-PLGA
was dissolved in 10 mL of acetone (solution A), and 10 mg
of HCPT was dissolved in 0.5 mL of 0.01 M NaOH so-
lution (solution B). Then, solution B was dropped into
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solution A and the mixture was used as the organic
phase. Subsequently, the resulting organic phase was
then introduced into a dialysis bag and dialyzed against
1000 mL of water as the aqueous phase for 8 h. The as-
prepared HCPT-loaded PEG-b-PLA nanoparticles (NPs)
were lyophilized for 24 h using a freeze drier and stored at
4 °C for use.
Preparation of the HCPT-Loaded NRs
The HCPT-loaded nanorods (NRs) were prepared via an
emulsion crystallization technique followed by the
lyophilization treatment. Briefly, 5 mg HCPT and 3 mg
PEG-b-PLGA were first co-dissolved in 5 mL acetone as
the oil phase, which was then added dropwise into deion-
ized water of 40 mL in volume under vigorous stirring.
Afterwards, the remaining organic solvent was removed
by the rotary vacuum evaporation at 37 °C. The produced
suspension was lyophilized for 24 h to get the dried
powder.
Characterization
The morphology of the HCPT-loaded NDs, NRs, and NSs
was examined by SEM (UV-70) at 20 kV. The average par-
ticle size and size distribution of the NDs were determined
by photon correlation spectroscopy with a Malvern Zetasi-
zer Nano-ZS (Malvern Instruments, Malvern) at 25 °C
under suitable dilution conditions. Measurements were re-
peated for three times to get the consistent results.
The amount of HCPT entrapped in the particles was
determined indirectly by UV spectrophotometry (Beck-
man DU800). All samples were assayed at 383 nm. The
weight of the drug entrapped in the particles was calcu-
lated by the calibration curve. Drug loading content and
entrapment efficiency are presented by Eqs. (1) and (2):
Drug loading content %ð Þ
¼ weight of drug in NPs
weight of NPs
 100 % ð1Þ
Entrapment efficiency %ð Þ
¼ weight of drug in NPs
weight of feeding drug
 100 %: ð2Þ
The crystalline form of HCPT loaded in the NDs was
analyzed using X-ray diffraction (XRD) (X'pert PRO).
The X-ray diffractogram was scanned with Cu-ka radi-
ation generated at 30 mA and 40 kV. The diffraction angle
was increasing from 5 to 60°, with a step size of 0.016°.
In Vitro Drug Release Studies
The in vitro drug release studies of particles were per-
formed using the dialysis technique. The HCPT-loaded
NDs were dispersed in phosphate-buffered saline (PBS,
10 mL) and placed into a pre-swelled dialysis bag
(MWCO 3500 Da). The dialysis bag was then immersed
in 0.1 M PBS at pH 7.4 and oscillated continuously in a
shaker incubator (100 rpm) at 37 °C. All samples were
assayed by fluorescence spectrophotometry. Free HCPT
at the equivalent concentrations were used for comparison.
Cellular Uptake Assay
Confocal imaging of cells was performed using a Leica
laser scanning confocal microscope. Imaging of HCPT
was carried out under 382-nm laser excitation, and
emission was collected in the range of 528 nm. HeLa
cells, MG-63 cells, MCF-7 cells, and MC3T3-E1 cells
were incubated with HCPT-loaded NDs, NRs, and NSs
([HCPT] = 1 mg/mL, the concentration of both particles
was determined by UV-vis measurement at 382 nm) for
0.5, 1.5, and 4.5 h before confocal imaging. All cells were
washed twice with PBS before confocal imaging.
Cytotoxicity of the NDs, NRs, and NSs
The cytotoxicity of the NDs, NRs, and NSs was deter-
mined by the MTT assay. Briefly, an adequate number of
exponential phase HeLa cells, MG-63 cells, and MCF-7
cells was plated in quintuplicate in a 96-well flat-bottomed
microplate and incubated for 24 h in the culture solution
containing NDs, NRs, NSs, or free HCPT. In this study,
20 mL of MTT (Sigma) solution (5 mg/mL in PBS) was
added in each well, and the plates were incubated at 37 °C
for another 4 h. This was followed by the addition of
150 mL dimethylsulfoxide (DMSO), and the plate was agi-
tated on a water bath chader at 37 °C for another 30 min.
The absorbance at 570 nm was measured using a micro-
plate reader (model 680; Bio-Rad).
Results and Discussion
Formulation and Characterization of the NDs
The NDs were prepared by an ultrasound-assisted emul-
sion crystallization method as shown in Fig. 1. HCPT
and PEG-b-PLGA were co-dissolved in acetone, forming
a hybrid solution of drug and excipient. By injecting the
hybrid solution into deionized water under sonication,
the nucleation of HCPT nanocrystallines and the accom-
panying co-precipitation of PEG-b-PLGA onto the grow-
ing HCPT nanocrystallines presumably occurred due to
a sudden change of solvent environment. Thus, the NDs
with nanocrystalline HCPT as the core wrapped with
Fig. 1 Schematic illustration of the preparation of NDs
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PEG-b-PLGA as steric stabilizers were prepared success-
fully. We found that the ratio of HCPT to PEG-b-PLGA
determined the morphology of the NDs, as shown in
Fig. 2. When the ratio of the drug to the excipient was
1:5, excess PEG-b-PLGA may not only hinder the
crystallization of HCPT, but also could not be fabricated
into the NDs and deposited a layer (Fig. 2c). When in-
creasing the amount of HCPT, NDs could be success-
fully manufactured (Fig. 2d). However, as the ratio was
increased to 2:1, the rod-shaped particles could be seen
in Fig. 1e, which were perhaps crystallized from the ex-
cess HCPT without the accompanying co-precipitation
of the PEG-b-PLGA.
Figure 2a, d shows the needle-shaped morphology of
the NDs with an average length of about 5 μm and a
width of about 400 nm. This was in according with the
TEM images (Fig. 2b). The result of DLS measurement
shows a size of 356.7 nm (Additional file 1: Figure S1)
and a zeta potential of −10.9 mv (Additional file 1:
Figure S2). In order to investigate the drug loading of
the NDs, ultraviolet spectroscopy was employed. It
follows that the drug loading content was 15.04 % and
the encapsulation efficiency was 30.08 %.
Since the form of a drug is an important factor that
affects the properties of the nanoparticles, it is highly
important to understand the form of HCPT in the
NDs. X-ray diffraction was employed to detect the form
of HCPT within the NDs (Fig. 3). It is clear that pure
HCPT shows many sharp crystalline peaks, representative
of the characteristics of high crystallinity. On the other
hand, a broad peak presents in PEG-b-PLGA, indicating
that PEG-b-PLGA is in the amorphous state. As to the
XRD pattern of the NDs, in addition to one broad and
weak peak attributed to the semicrystalline PEG-b-PLGA,
a number of sharp peaks of crystalline HCPT occur, the
same as their bulk counterparts, suggesting its high crys-
tallinity within the NDs. In short, the XRD results suggest
that the growth kinetics of HCPT within the NDs had
been changed, mainly due to the active occlusion and con-
fining effects of PEG-b-PLGA.
In Vitro Drug Release Studies
The core-shell architecture of NDs plays an important
role in the effect of sustained release of HCPT. The in
vitro release studies of the NDs were performed using a
dialysis technique, alongside free HCPT powders. All
samples were assayed by fluorescence spectrophotom-
etry (excitation at 382 nm). The release profiles are
shown in Fig. 4. The profile of free HCPT showed that
40 % of the drug was released at the first sampling time
of 1 h and almost 100 % by 8 h. The release profile of
the NDs appears to have two components with a slight
Fig. 2 The SEM images and TEM images. a SEM image of the NDs. b TEM image of the NDs. And, SEM images of the NDs, when the ratio of
HCPT to PEG-b-PLGA was 1:5 (c), 1:1 (d), and 2:1 (e)
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burst release of about 35 % at the sampling time of 8 h
and followed by a remarkably prolonged release over the
next 380 h. Although, the burst release still existed, it
was reduced to a very low degree and the duration of
sustained drug release had been prolonged to about
400 h. This can be attributed to the fact that a polymeric
shell could limit the release of the drug in the core.
These advantages could promote the application of the
NDs for a sustained local drug delivery system.
Cellular Uptake of the NDs by Cancer Cells
Confocal microscopy and fluorescence measurements
were performed to assess the cellular uptake of NDs.
Three types of cancer cells (HeLa cells, MG-63 cells,
and MCF-7 cells) and one type of normal cell (MC3T3-
E1 cells) were incubated with NDs for 0.5, 1.5, and 4.5 h,
at 37 °C and then washed using PBS several times to re-
move the excess NDs: HCPT-loaded NSs with a drug
loading of 7.0 % and a size distribution of 120.1 nm [49],
collected from the dialysis method (see in the SI mate-
rials), and HCPT-loaded NRs with a drug loading of
35.2 % and a size distribution of 140 nm, collected from
the emulsion crystallization method were used for com-
parison. The NSs and the NRs were prepared with the
same materials—HCPT and PEG-b-PLGA—and thus
they were detected to be with the similar properties such
as the zeta potential. This was also found to affect the
cellular uptake to a large degree. With a size of 120 nm
(Additional file 1: Figure S3), the NSs were much smaller
than the NDs and the NRs (Additional file 1: Figure S4),
which should have been taken up much faster and much
more than the two larger particles [12–17]. But, the re-
sult did not come out as expected.
It follows from Fig. 5 that a much more intense fluor-
escence emission of HCPT was detected from all the
four types of cells exposed to the NDs and the NRs than
that of those exposed to NSs for the same sampling
time. As shown in Fig. 5b, c, a relatively intense fluores-
cence of HCPT was detected from the HeLa cells exposed
to the NDs and the NRs for 0.5 h. And, the intensity of
fluorescence increased with the incubate time, indicating
that the uptake of the NDs and the NRs began before the
first sample time of 0.5 h, and amounts of NDs had been
internalized into the HeLa cells at 0.5 h. But, as to the
HeLa cells exposed to the NSs, no fluorescence could be
detected under the same intensity of the excitation light at
0.5 and 1.5 h (Fig. 5a). Hence, the intensity of the excita-
tion light was raised, and a weak fluorescence appeared
(Additional file 1: Figure S5 A and B). The result indicates
that very few NSs were internalized by the HeLa cells after
incubating with the particles for 0.5 and 1.5 h. But, a rela-
tively strong fluorescence emission was detected at the
sample time of 4.5 h (Fig. 5a), illustrating that more NSs
were internalized into the HeLa cells. Hence, the uptake
of the majority of NSs by the HeLa occurred between 1.5
and 4.5 h, which was much later than that of the NDs and
the NRs. Moreover, in comparing Fig. 5a with Fig. 5b, c,
the fluorescence detected from the group of 0.5 h NDs
and NRs incubation was stronger than that of 4.5 h NSs
incubation, indicating that the amount of NDs and the
NRs internalized into the HeLa cells was much more than
that of the NSs. As to the MG-63 cells, MCF-7 cells, and
MC3T3-E1 cells, identical results were acquired; the fluor-
escence emissions detected from the cells incubated with
the NDs and the NRs were much earlier and stronger than
that of the cells incubated with the NSs (Fig. 5c–h). These
results distinctly demonstrated that a high-aspect ratio
can increase the abundance and the rate of cellular uptake
of the particles. And, this factor might play a more import-
ant role than the size of the particle.
Comparing Fig. 5b, and Fig. 5c, the fluorescence emis-
sion of HCPT from the cells exposed to the NDs was a
Fig. 3 The XRD patterns of a free HCPT, b PEG-b-PLGA, and
c HCPT-loaded NDs
Fig. 4 The drug release profile of free HCPT and HCPT-loaded NDs
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little stronger than that of those exposed to the NRs at
each simple time. With a similar aspect ratio, it might
be the pointed end that influences the internalization of
the particles. Furthermore, when normal cells (MC3T3-
E1 cells) were incubated with the particles, the intensity
of the fluorescence signal was much weaker than that of
the cancer cells. This was probably because the mem-
brane fluidity of the cancer cells were elevated, which
would facilitate the internalization of the particles.
The drug amount difference in cellular uptake among
the NRs, NDs, and NSs could be attributed to both the
released drug and drug trapped inside the nanoparticles,
no matter how much the ratio of PEG-b-PLGA to HCPT
is. The cellular uptake time was designed between 0.5
and 4.5 h, in which a little amount of the drug was re-
leased (seen from the drug release profile), so the drug
taken up in the cell was much due to the drug inside the
nanoparticles. In addition, the drug release profile of
NRs was not significantly different from that of the NDs
(See Additional file 1: Figure S6). So, the difference is
mainly attributed to the shapes of nanoparticles instead
of the released drug from the particles or the ratio of
PEG-b-PLGA to HCPT.
The process in which the drug was first released into
the extracellular medium and diffused into cells truly
happened in the experiment. To further verify the role
Fig. 5 The CLSM images. The HeLa cells, MG-63 cells, MCF-7 cells, and MC3T3-E1 cells incubated with HCPT-loaded NSs ([HCPT] = 1 mg/mL),
HCPT-loaded NRs ([HCPT] = 1 mg/mL), and NDs ([HCPT] = 1 mg/mL) for 0.5 h (a), 1.5 h (b), and 4.5 h (c) at 37 °C, respectively. All images were
taken under identical instrumental conditions and presented at the same intensity scale. All scale bars are 25 μm
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of the released drug property in cellular uptake, free
HCPT was used as control in the cellular uptake experi-
ment. But just as mentioned above, the longest incubation
time was only 4.5 h, during which the amount of released
drug was <20 %. Hence, we used free HCPT (the concen-
tration was 20 % of that of the NDs) as control. Since a
much more intense fluorescence signal of HCPT was de-
tected from the HeLa cells exposed to the NDs than that
of those exposed to free HCPT (See Additional file 1:
Figure S7), the fluorescence in the HeLa cells was mainly
caused by the internalization of the NDs, rather than that
of HCPT. In effect, the different shapes of nanoparticles in
the extracellular medium were just like cocci or bacillus
with a little bit of soft property. Once the nanoparticles
were taken up by the cells, the particles were immediately
swallowed by the lysosome,in which the different shapes
of particles were all decomposed into fragments by a var-
iety of decomposition enzymes.
Taking the size effect into account, the NSs with a
much smaller size should have been much more favored
in the cellular internalization process. However, the op-
posite was observed; the confocal laser scanning micros-
copy (CLSM) images further validate that the cellular
internalization of the nanoparticles exhibits a strong shape
dependence, which may be stronger than the influence of
size. The results demonstrate the following fact: the high-
aspect-ratio nanoparticles are internalized much more
rapidly and efficiently than those with the equal aspect ra-
tio [48]. Moreover, the phagocytosis may also be in favor
of the particles with sharp ends. Champion JA et al. found
that a macrophage attached to an ellipse at the pointed
end will internalize the particle in a few minutes, while a
macrophage attached to a flat region of the same ellipse
will not internalize it for over 12 h. Here, we define the
angle Φ to roughly illustrate the role of shape in non-
phagocytosis uptake (Fig. 6). M and N are vectors that
show the flow directions of the cell membranes. Φ is the
angle between M and N. The cell membranes flow easily,
when the Φ is small. The Φ of the NDs is 10.19 ± 1.47°
(Fig. 6b), much smaller than 90° of the NDs. When the
NDs were attached to the HeLa cells at the sharp end, they
would be taken up in a short time, mainly less than 0.5 h.
This explains the fact that Fig. 5d shows a more intense
fluorescent emission. When the NDs attached to the HeLa
cells at the flat region, they would change the orientation
until being taken up. As to the NRs, their internalization
began from the vertexes and the Φ was 90°, which took
more time to complete the uptake. And, the Φ of the NSs
was much larger than 90°, which took the longest time.
Notably, it was believed that the upper limit of the size
that can be taken up into non-phagocytic cells was 150 nm.
In the study herein, however, the internalization of NDs
with an average length between 5 μm was clearly observed
in CLSM images. Therefore, the particle size, measured
simply by diameter for spheres, must have a new definition
to non-spherical particles since they may have two or more
different length scales. And, the new definition should take
into account the end, the angle, the asymmetry, and some
other factors of the non-spherical particles to make it more
accurate.
Cytotoxicity of the NDs, NRs, and NSs
To further investigate the possibility of utilizing the NDs
for local drug delivery, we tested the killing ability of the
NDs to cancer cells. The cytotoxicity of NDs, NRs, NSs,
Fig. 6 Definition of Φ and the schematic illustration of the internalization of NDs, NRs, and NSs (a–c). M and N are vectors that show the flow
directions of the cell membranes. Φ is the angle between M and N . d The measurement of the Φ of the NDs. e–f The SEM of the NRs and NSs
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and free HCPT was evaluated using the MTT assay with
the HeLa cells, MG-63 cells, and MCF-7 cells. The NDs,
NSs, and free HCPT containing the equivalent concen-
trations of HCPT were, respectively, incubated with the
three types of cells for 24 and 48 h.
It shows in Fig. 7 that the NDs and the NRs reveal a
much higher degree of toxicity to the HeLa cells than
that of the NSs at 24 h at equivalent concentrations of
HCPT. The possible explanation is as follows. Firstly, be-
cause of the enhanced cellular uptake, more NDs and
NRs could be taken up by the HeLa cells, and release
more HCPT in the cells, which kills the cells instantly.
Secondly, for its high drug loading, the NDs and the
NRs have a slight burst release at 8 h, resulting in the
fact that the HCPT concentration in the group of NDs
was higher than that of the NSs both in and out of the
cells. And, the difference of the cell viability between the
group of NDs and NSs became more obvious at 48 h,
owing to the fact that the influence of the above two fac-
tors became larger when the incubated time was pro-
longed to 48 h. Meanwhile, we could still find that the
NDs’ toxicity was higher than that of the NRs’, which
might be owing to the enhanced cellular uptake of the
NDs caused by the sharp end. Compared with the three
kinds of NPs, free HCPT shows the highest inhibition
rate, mainly due to the fact that free HCPT could in-
crease the drug concentration to a high level within a
short time and directly acted on the cells. As to the
other two types of cells, although their sensitivity to
HCPT was different from the HeLa cells, the order of
the killing ability was free HCPT > NDs > NRs > NSs
(Additional file 1: Figure S6). This was in accordance
with the result of the HeLa cells.
Conclusions
The study herein presents a simple approach to obtain
the HCPT-loaded, high-aspect- ratio, pointed-end NDs
with high drug loading content and sustained drug re-
lease. The CLSM demonstrates the more effective cellu-
lar internalization of NDs than that of nanospheres with
a much smaller size. The MTT experiment indicated
that the NDs show an enhanced cytotoxicity to the three
types of cells. Although the NDs are too large to be used
as systemic injections, the NDs are promising as a sus-
tained local drug delivery system for the treatment of
tumor for their easier internalization and high cytotox-
icity to the cancer cells. More importantly, the fabrica-
tion of NDs opens a door to design new formulations of
nanoneedle drug delivery systems, or at least nanorod
drug delivery systems, which are more efficient in cancer
chemotherapy compared with the spherical nanodrug
delivery system.
Additional File
Additional file 1: Figure S1. The size distribution of HCPT-loaded NDs.
Figure S2. The Zeta Potential of HCPT-loaded NDs. Figure S3. The SEM
images of HCPT-loaded NSs. Figure S4. The SEM images of HCPT-loaded
NRs. Figure S5. The CLSM images at higher intensity scale. HeLa cells
incubated with HCPT-loaded NSs ([HCPT] = 1 mg/mL) for A) 0.5 h and B)
1.5 h. C) MG-63 cells incubated with HCPT-loaded NSs ([HCPT] = 1 mg/mL) for
0.5 h. D) MCF-7 cells incubated with HCPT-loaded NSs ([HCPT] = 1 mg/mL) for
0.5 h. MC3T3-E1 cells incubated with HCPT-loaded NSs ([HCPT] = 1 mg/mL) for
Fig. 7 The in vitro cytotoxicity assay against the HeLa cells, p < 0.05
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E) 0.5 h and F) 1.5 h. Figure S6. In vitro drug release profiles of NDs, NRs
and NSs in PBS (pH 7.4) at 37 °C. Figure S7. The CLSM images. The
HeLa cells incubated with (A) free HCPT ([HCPT] = 0.2 mg/mL), and (B)
NDs ([HCPT] = 1 mg/mL) for 4.5 h at 37 °C. All images were taken under
identical instrumental conditions and presented at the same intensity
scale. All scale bars are 25 μm. Figure S8. The in vitro cytotoxicity assay
against the MG-63 cells (A) and the MCF-7 cells (B), p < 0.05. (DOC 1389 kb)
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